全文获取类型
收费全文 | 32326篇 |
免费 | 2411篇 |
国内免费 | 390篇 |
专业分类
耳鼻咽喉 | 354篇 |
儿科学 | 901篇 |
妇产科学 | 759篇 |
基础医学 | 4146篇 |
口腔科学 | 728篇 |
临床医学 | 3372篇 |
内科学 | 5924篇 |
皮肤病学 | 709篇 |
神经病学 | 2817篇 |
特种医学 | 1046篇 |
外国民族医学 | 3篇 |
外科学 | 4210篇 |
综合类 | 1235篇 |
一般理论 | 28篇 |
预防医学 | 2727篇 |
眼科学 | 785篇 |
药学 | 2355篇 |
5篇 | |
中国医学 | 291篇 |
肿瘤学 | 2732篇 |
出版年
2024年 | 140篇 |
2023年 | 231篇 |
2022年 | 468篇 |
2021年 | 697篇 |
2020年 | 467篇 |
2019年 | 647篇 |
2018年 | 651篇 |
2017年 | 563篇 |
2016年 | 576篇 |
2015年 | 749篇 |
2014年 | 955篇 |
2013年 | 1379篇 |
2012年 | 1952篇 |
2011年 | 2041篇 |
2010年 | 1225篇 |
2009年 | 1084篇 |
2008年 | 1793篇 |
2007年 | 1828篇 |
2006年 | 1807篇 |
2005年 | 1739篇 |
2004年 | 1576篇 |
2003年 | 1478篇 |
2002年 | 1378篇 |
2001年 | 650篇 |
2000年 | 601篇 |
1999年 | 622篇 |
1998年 | 380篇 |
1997年 | 335篇 |
1996年 | 330篇 |
1995年 | 306篇 |
1994年 | 260篇 |
1993年 | 261篇 |
1992年 | 391篇 |
1991年 | 377篇 |
1990年 | 368篇 |
1989年 | 339篇 |
1988年 | 292篇 |
1987年 | 239篇 |
1986年 | 292篇 |
1985年 | 264篇 |
1984年 | 248篇 |
1983年 | 223篇 |
1982年 | 246篇 |
1981年 | 228篇 |
1980年 | 176篇 |
1979年 | 209篇 |
1978年 | 147篇 |
1977年 | 149篇 |
1976年 | 139篇 |
1974年 | 163篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
61.
目的:骨髓间质干细胞体外诱导和非诱导培养向心肌细胞分化的结果的对比。方法:实验于2003-03/2004-12在阜外心血管病医院中心实验室完成。①分离犬骨髓间质干细胞。②于体外培养,应用不同浓度(0,6,8,10,12,14,20μmol/L)的5-氮胞苷定向诱导并连续传代培养4周,未诱导的细胞培养8周。③进行细胞形态学、细胞免疫组织化学、透射电镜鉴定。结果:(D骨髓间质于细胞于5-氮胞苷诱导培养2周时,α-肌动蛋白、TroponinI染色阴性;4周时,α-肌动蛋白染色阳性,Troponin I阴性;电镜下可见肌丝结构,其中8mmol/L 5-氮胞苷诱导的间质干细胞肌丝结构排列较规则。②骨髓间质干细胞非诱导培养8周时,α-肌动蛋白染色阳性,Troponin I阴性,电镜下亦可见肌丝结构形成;而培养4周时全部为阴性。结论:骨髓间质干细胞经5-氮胞苷诱导培养4周及未诱导连续培养8周均可定向转化为具有肌丝结构的肌样细胞,而非心肌样细胞。 相似文献
62.
63.
Quyen D. Chu Meijiao Zhou Prakash Peddi Kaelen L. Medeiros Xiao-Cheng Wu 《Surgery》2018,163(6):1213-1219
Background
The Cancer and Leukemia Group B 9,343 demonstrated that postoperative radiation can be safely omitted in women ≥70 years who underwent breast-conserving therapy for clinical stage I (T1N0M0) estrogen receptor positive breast cancer treated with antihormonal therapy. Whether such results are observed in real-world population is unknown. In this hospital-based data, we report the survival outcomes of patients who received adjuvant radiation therapy versus those who did not.Methods
Using the National Cancer Data Base, we evaluated a cohort of 47,358 women with newly diagnosed breast cancer between 2004 and 2011 who underwent a lumpectomy and antihormonal therapy with the following criteria: age ≥70 years, clinical stage I, estrogen receptor positive, and negative margins. Patients were stratified into 2 groups: (1) radiation therapy and (2) no radiation therapy. Propensity score matching was used to compensate for differences in demographic and clinical characteristics of the patients. Univariate and multivariable survival analysis were employed to determine factors associated with overall survival.Results
The 5-year overall survival after propensity score matching was 87.2% for radiation therapy and 79.4% for no radiation therapy (P?<?.0001). The median survival time was 113.7 months for radiation therapy and 105.2 months for no radiation therapy. After adjusting for sociodemographic and clinical factors, the risk of overall deaths was significantly higher for those not receiving radiation therapy (hazard ratio?=?1.66; 95% confidence interval, 1.54–1.79). Other significant adjusted predictors (P?<?.05) of poor overall survival were, advanced age, comprehensive community cancer program, facility location, poorly differentiated tumor, and high comorbidity index.Conclusion
Patients who received radiation therapy had better survival outcomes than those who did not, revealing discordance between results of randomized trials and real-world setting. 相似文献64.
65.
66.
Fenton H. McCarthy Sreekanth Vemulapalli Zhuokai Li Vinod Thourani Roland A. Matsouaka Nimesh D. Desai Ajay Kirtane Saif Anwaruddin Matthew L. Williams Jay Giri Prashanth Vallabhajosyula Robert H. Li Howard C. Herrmann Joseph E. Bavaria Wilson Y. Szeto 《The Annals of thoracic surgery》2018,105(4):1121-1128
67.
Daniel E. Spratt Robert T. Dess Zachary S. Zumsteg Daniel W. Lin Phuoc T. Tran Todd M. Morgan Emmanuel S. Antonarakis Paul L. Nguyen Charles J. Ryan Howard M. Sandler Matthew R. Cooperberg Edwin Posadas Felix Y. Feng 《European urology》2018,73(2):156-165
Context
Salvage radiotherapy (SRT) is a standard of care for men who recur postprostatectomy, and recent randomized trials have assessed the benefit and toxicity of adding hormone therapy (HT) to SRT with differing results.Objective
To perform a systematic review of randomized phase III trials of the use of SRT ± HT and generate a framework for the use of HT with SRT.Evidence acquisition
Systematic literature searches were conducted on February 15, 2017 in three databases (MEDLINE [via PubMed], EMBASE, and ClinicalTrials.gov) for human-only randomized clinical trials from January 30, 1990, through January 30, 2017. Only two randomized trials met all inclusion criteria.Evidence synthesis
Overall survival benefits from HT were found in one trial, which was limited to when follow-up extended to ≥10 yr, pre-SRT prostate-specific antigen (PSA) ≥0.7 ng/ml, or when higher Gleason grade or positive margins were present. Both trials demonstrated a benefit from HT in men with higher pre-SRT PSAs. Three prognostic factors appeared to discriminate improvements in meaningful clinical endpoints (eg, distant metastasis or survival): pre-SRT PSA, Gleason score, and margin status. Two years of bicalutamide monotherapy resulted in higher rates of gynecomastia with a trend for worse survival when given in favorable risk patients, and 6 mo of luteinizing hormone–releasing hormone agonist therapy resulted in higher rates of hot flashes and long-term hypertension.Conclusions
Similar to the selective use of HT with radiotherapy in localized prostate cancer, not all patients appear to derive a meaningful benefit from HT with SRT. Patient, tumor, and treatment factors must be considered when recommending the use of HT with SRT. Knowledge gaps exist in the level 1 data regarding the optimal duration and type of HT, as well as the ability to use predictive biomarkers to personalize the use of HT with SRT. Important clinical trials (RADICALS and NRG GU-006) are aimed to answer these questions.Patient summary
In this report, we performed a systematic review of the literature to determine the benefit and harm of adding hormone therapy to salvage radiotherapy (SRT) for recurrent prostate cancer. We found that the benefit of hormone therapy varied by important prognostic factors, including pre-SRT prostate-specific antigen, Gleason grade, and surgical margin status. Our group then developed a framework on how best to utilize hormone therapy with SRT. 相似文献68.
Bernard Escudier Padmanee Sharma David F. McDermott Saby George Hans J. Hammers Sandhya Srinivas Scott S. Tykodi Jeffrey A. Sosman Giuseppe Procopio Elizabeth R. Plimack Daniel Castellano Howard Gurney Frede Donskov Katriina Peltola John Wagstaff Thomas C. Gauler Takeshi Ueda Huanyu Zhao Robert J. Motzer 《European urology》2018,73(4):e116-e118
69.
70.
Lynne?MooreEmail author Howard?Champion Pier-Alexandre?Tardif Brice-Lionel?Kuimi Gerard?O’Reilly Ari?Leppaniemi Peter?Cameron Cameron?S.?Palmer Fikri?M.?Abu-Zidan Belinda?Gabbe Christine?Gaarder Natalie?Yanchar Henry?Thomas?Stelfox Raul?Coimbra John?Kortbeek Vanessa?K.?Noonan Amy?Gunning Malcolm?Gordon Monty?Khajanchi Teegwendé?V.?Porgo Alexis?F.?Turgeon Luke?Leenen On behalf of the International Injury Care Improvement Initiative 《World journal of surgery》2018,42(5):1327-1339